JP2007514749A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514749A5
JP2007514749A5 JP2006545434A JP2006545434A JP2007514749A5 JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5 JP 2006545434 A JP2006545434 A JP 2006545434A JP 2006545434 A JP2006545434 A JP 2006545434A JP 2007514749 A5 JP2007514749 A5 JP 2007514749A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
toxoid
clostridium difficile
antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006545434A
Other languages
English (en)
Japanese (ja)
Other versions
JP4904163B2 (ja
JP2007514749A (ja
Filing date
Publication date
Priority claimed from US10/737,270 external-priority patent/US6969520B2/en
Application filed filed Critical
Publication of JP2007514749A publication Critical patent/JP2007514749A/ja
Publication of JP2007514749A5 publication Critical patent/JP2007514749A5/ja
Application granted granted Critical
Publication of JP4904163B2 publication Critical patent/JP4904163B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006545434A 2003-12-16 2004-12-15 クロストリジウムディフィシル疾患に対する受動免疫感作 Expired - Fee Related JP4904163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/737,270 2003-12-16
US10/737,270 US6969520B2 (en) 1997-10-20 2003-12-16 Active immunization against clostridium difficile disease
PCT/US2004/042277 WO2005058353A1 (en) 2003-12-16 2004-12-15 Passive immunization against clostridium difficile disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011195944A Division JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作

Publications (3)

Publication Number Publication Date
JP2007514749A JP2007514749A (ja) 2007-06-07
JP2007514749A5 true JP2007514749A5 (https=) 2008-07-03
JP4904163B2 JP4904163B2 (ja) 2012-03-28

Family

ID=34700454

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006545434A Expired - Fee Related JP4904163B2 (ja) 2003-12-16 2004-12-15 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2011195944A Expired - Lifetime JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2015149504A Ceased JP2015205919A (ja) 2003-12-16 2015-07-29 クロストリジウムディフィシル疾患に対する受動免疫感作

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011195944A Expired - Lifetime JP6130622B2 (ja) 2003-12-16 2011-09-08 クロストリジウムディフィシル疾患に対する受動免疫感作
JP2015149504A Ceased JP2015205919A (ja) 2003-12-16 2015-07-29 クロストリジウムディフィシル疾患に対する受動免疫感作

Country Status (7)

Country Link
US (6) US6969520B2 (https=)
EP (2) EP1708743B1 (https=)
JP (3) JP4904163B2 (https=)
AU (2) AU2004299105B8 (https=)
CA (1) CA2550108C (https=)
DK (1) DK1708743T3 (https=)
WO (1) WO2005058353A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB0306782D0 (en) * 2003-03-25 2003-04-30 Neutec Pharma Plc Treatment of infection due to clostridium difficile
US20070280949A1 (en) * 2003-07-10 2007-12-06 Michelle Alfa Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
BRPI0415703A (pt) * 2003-10-24 2006-12-19 Univ Queensland expressão de proteìna
WO2005106598A1 (ja) * 2004-04-28 2005-11-10 Canon Kabushiki Kaisha トナー
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CN101374547A (zh) * 2005-12-22 2009-02-25 财团法人化学及血清疗法研究所 卵内接种用疫苗
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
PL2198007T3 (pl) * 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2329029B1 (en) * 2008-09-24 2016-06-08 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
AU2010215275B2 (en) 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
JP5408017B2 (ja) * 2009-06-05 2014-02-05 株式会社デンソー 蓄冷熱交換器
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
JP6017452B2 (ja) 2011-01-19 2016-11-02 アクセスクロージャー，インク． 血管穿刺のシーリング装置及びシーリング方法
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
AR090219A1 (es) 2012-03-02 2014-10-29 Regeneron Pharma Anticuerpos humanos frente a toxinas de clostridium difficile
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN105142612A (zh) 2013-03-08 2015-12-09 奇普拉股份有限公司 用于直肠给药的药物组合物
EP2969012A4 (en) 2013-03-12 2016-09-14 Univ Yale COMPOSITIONS AND METHODS FOR IDENTIFYING SEQUENCEL ANTIBODY-BONDED MICROBES
KR20150133771A (ko) * 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
US20160045586A1 (en) * 2013-03-15 2016-02-18 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
CA2909636C (en) * 2013-04-19 2023-08-22 Dena Lyras Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
AU2014277981B2 (en) * 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
WO2016033439A2 (en) * 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
US20180085458A1 (en) * 2015-04-15 2018-03-29 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US968199A (en) * 1909-11-24 1910-08-23 Nathan Schwartz Muffler.
US4581020A (en) * 1983-07-18 1986-04-08 Trimedyne, Inc. Medication delivery device and system for percutaneous administration of medication
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5599539A (en) * 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
WO1992018652A1 (en) * 1991-04-22 1992-10-29 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
EP0680337A4 (en) 1993-01-12 1997-07-30 Anthony George Gristina METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY.
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
EP0779819A1 (en) * 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
ATE272409T1 (de) * 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20050106157A1 (en) * 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US20040106590A1 (en) * 2002-08-29 2004-06-03 Barry Eisenstein Methods and reagents for treating infections of clostridium difficile and diseases associated therewith

Similar Documents

Publication Publication Date Title
JP2007514749A5 (https=)
JP2005524663A5 (https=)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2006501240A5 (https=)
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
JP2015519329A5 (https=)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2009500443A5 (https=)
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
JP2013503165A5 (https=)
JP2009515901A5 (https=)
OA12845A (en) Single dose azithromycin for treating respiratory infections.
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
JP2006514681A5 (https=)
JP2002530353A5 (https=)
JP2009500045A5 (https=)
Ramam et al. A two-step schedule for the treatment of actinomycotic mycetomas
JP2005507888A5 (https=)
CA2519789A1 (en) Aplidine for multiple myeloma treatment
Wilson Streptomycin in Non-tuberculous Infections
Buckland et al. Upper limb morbidity as a direct consequence of intravenous drug abuse
JP2018534306A5 (https=)
JP2011500650A5 (https=)
JP2002529515A5 (https=)